Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Sees Large Decrease in Short Interest

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totaling 3,571 shares, a decline of 94.5% from the June 30th total of 65,392 shares. Based on an average trading volume of 99,268 shares, the short-interest ratio is presently 0.0 days. Currently, 0.4% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Cuprina Holdings (Cayman) from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Cuprina Holdings (Cayman) Stock Performance

Cuprina Holdings (Cayman) stock traded up $0.03 during mid-day trading on Friday, hitting $3.34. 12,799 shares of the company were exchanged, compared to its average volume of 1,379,201. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.35 and a quick ratio of 2.35. The business has a fifty day moving average of $3.91. Cuprina Holdings has a 1-year low of $1.76 and a 1-year high of $76.00.

Cuprina Holdings (Cayman) (NASDAQ:CUPR) last issued its earnings results on Monday, April 27th. The company reported ($0.40) EPS for the quarter. The firm had revenue of $0.01 million for the quarter.

About Cuprina Holdings (Cayman)

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.